"For people with hereditary antithrombin deficiency, the risk of clinically relevant DVT when undergoing surgery or childbirth is in the neighborhood of 30%."
Yes but the question posed was: "how often does DVT happen w/ plasma antithrombin?" not if these patients were not treated at all. I guess we do not have a comparative data for patients treated with plasma antithrombin...
In either case, the results certainly prove non-inferiority since we had Zero DVT's here. The question now is how high do we go tomorrow on that news? You Dew had previously hinted at $1.2 being the upside for this news alone. Personally, I think we could go much higher but we shall see...
Market Data 
Markets 
AI
